Navigation Links
Gardasil Effective in Preventing Vaginal, Vulvar Cancers, Study Finds

Merck's human papillomavirus vaccine Gardasil is effective in preventing vaginal and vulvar tumors, according to a study to be published on Saturday in the journal Lancet, Dow Jones reports.

Gardasil in clinical trials has been shown to be 100% effective in preventing infection with strains 16 and 18, which together cause about 70% of cervical cancer cases, and about 99% effective in preventing HPV strains 6 and 11, which together with HPV strains 16 and 18 cause about 90% of genital wart cases, among women not already infected with these strains.

FDA in June 2006 approved Gardasil for sale and marketing to girls and women ages nine to 26, and CDC's Advisory Committee on Immunization Practices later that month voted unanimously to recommend that girls ages 11 and 12 receive the vaccine, which is given in a three-shot series. Merck last month announced that it has submitted an application to FDA for extended approval of Gardasil to help prevent vaginal and vulvar cancers.

After three years of follow-up, the study found that the vaccine was 71% effective in preventing vaginal and vulvar cancers related to HPV strains 16 and 18 among women who previously had been exposed to HPV strains 6, 11, 16 and 18.

It was 100% effective among women who previously had not been exposed to those strains. The vaccine was not effective in fighting vaginal or vulvar lesions that had already formed, according to the study.

According to Merck, vaginal and vulvar cancers account for about 3% and 4% of gynecological cancers, respectively. According to HealthDay News/Forbes, HPV is present in about 80% of the 6,000 vaginal and vulvar cancers diagnosed annually in the U.S.


Page: 1

Related medicine news :

1. Gardasil vaccine for cervical cancer
2. Gardasil- Cervical Cancer Vaccine Now Approved
3. Gardasil, a cervical cancer vaccine, hits the market
4. Gardasil Hailed as one of the Biggest Research Successes
5. Cervical Cancer Vaccine Gardasil Included In Subsidized CDC program
6. Gardasil Refused Subsidy
7. School Vaccination Program to Include Cancer Drug Gardasil
8. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
9. Gardasil – Cervical Cancer Vaccine in UA
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
Post Your Comments:

(Date:11/30/2015)... , ... November 30, 2015 , ... ... Solutions, announced at the Radiology Society of North America (RSNA) annual meeting, being ... over 60% growth from 2014. Throughout 2015, the company has completed installations ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors ... independent living, assisted living and all other retirement options. Support for issues surrounding ... research remains a top priority. , So it’s no surprise that every ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming Dec. 8 virtual conference ... Health and UCare, MissionPoint Health Partners, and Intel Corp. Leaders from these ...
(Date:11/30/2015)... ... 30, 2015 , ... Vasont Systems, a top component content ... extension unites with Syncro Soft’s latest software update, oXygen XML editor Version 17.1. ... the latest release of oXygen® XML editor and the Vasont® CCMS. , ...
(Date:11/30/2015)... ... November 30, 2015 , ... Scott ... one of a select few plastic surgeons in the New York City area ... SculpSure™ is the world’s first heat-induced laser treatment for fat loss in the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)...  Novartis will demonstrate the strength of its research ... Society of Hematology (ASH) Annual Meeting. Presentations will highlight ... supportive care, including key findings in rare and difficult-to-treat ... ASH Annual Meeting will be held December 5-8 in ... Oncology . "We will be presenting encouraging overall survival ...
(Date:11/30/2015)... REHOVOT, Israel , Nov. 30, 2015 ... focused on acquiring and developing innovative therapies for ear, ... of Keith A. Katkin as chairman of ... Flesher , chief executive officer for OticPharma, Ltd.  "Keith ... As chairman, he will be able to share this ...
Breaking Medicine Technology: